U.S. market Open. Closes in 3 hours 10 minutes

BLCM | Bellicum Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BLCM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is good and Health is frighteningly weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -0.11 -23.05
PEG Ratio (TTM) -0.01 15.47
P/S Ratio (TTM) 0.52 49.46
P/B Ratio (TTM) -0.09 18.87
P/FCF Ratio (TTM) -0.03 -3.27
Price to 5YR AVG Earnings Ratio -0.01 -3.55
Price to 5YR AVG FCF Ratio -0.01 -9.37

Profitability (50%)

Company Industry
ROA (TTM) -318.07% -5.14%
ROE (TTM) 153.34% 16.69%
Net Profit Margin (TTM) -1,445.43% -1,583.93%
ROIC 5YR AVG 295.62% 15.15%

Growth (68%)

4QTR AVG 3YR AVG 5YR AVG
EPS -45.63% 33.21% 29.34%
Revenue -62.10% 316.72% 402.87%
Net Income 21.31% 19.24% -22.83%
Cash Flow 11.66% 6.93% 13.68%

Health (21%)

Company Industry
Current Ratio (TTM) 3.04 6.13
Quick Ratio (TTM) 2.63 5.85
D/E Ratio (TTM) N/A -15.81
Interest Coverage (TTM) 39.08 -1.57
Piotroski F-Score N/A 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF N/A 0.17
Shares Outstanding Growth 5YR AVG 66.79% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙